Severe dawn phenomenon predicts long‐term risk of all‐cause mortality in patients with type 2 diabetes
Diabetes/Metabolism Research and Reviews · 2024
DOI: 10.1002/dmrr.3813 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes/Metabolism Research and Reviews, 2024. Verfasst von Jinghao Cai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Blood Glucose. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shanghai Municipal Project for Academic Leaders Public Health, Shanghai Municipal Key Clinical Specialty, Shanghai "Rising Stars of Medical Talent" Youth Development Program-Outstanding Youth Medical Talents.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
The dawn phenomenon (DP) is an abnormal early morning blood glucose rise without nocturnal hypoglycaemia, which can be more easily and precisely assessed with continuous glucose monitoring (CGM). This prospective study aimed to explore the association between DP and the risk of all‐cause mortality in patients with type 2 diabetes. Materials and Methods A total of 5542 adult inpatients with type 2 diabetes in a single centre were analysed. The magnitude of DP (ΔG) was defined as the increment in the CGM‐determined glucose value from nocturnal nadir (after 24:00) to prebreakfast. Participants were stratified into four groups by ΔG: ≤1.11, 1.12–3.33, 3.34–5.55, and >5.55 mmol/L. Cox proportional hazard regression models were used to evaluate the impact of DP on all‐cause mortality risk.
Results
During a median follow‐up of 9.4 years, 1083 deaths were identified. The restricted cubic spline revealed a nonlinear ( p for nonlinearity = 0.002) relationship between ΔG and the risk of all‐cause mortality. A multivariate‐adjusted Cox regression model including glycated haemoglobin A1c (HbA1c) showed that ΔG > 5.55 mmol/L was associated with 30% (95% CI, 1.01–1.66) higher risk of all‐cause mortality, as compared with ΔG 1.12–3.33 mmol/L.
Conclusions
Higher ΔG is significantly related to an increased risk of all‐cause mortality in type 2 diabetes, suggesting that severe DP should be given more attention as a part of glucose management to reduce the risk of long‐term adverse outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai K…
- Vital Statistical Department, Institute of Health Information, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
ORCID-Profile: Jian Zhou
Förderung
- Shanghai Municipal Project for Academic Leaders Public Health
- Shanghai Municipal Key Clinical Specialty
- Shanghai "Rising Stars of Medical Talent" Youth Development Program-Outstanding Youth Medical Talents
- National Natural Science Foundation of China
- Program of Shanghai Academic Research Leader
Zitieren
APA
Cai, J., Peng, P., Lu, J., Shen, Y., Wang, C., Mo, Y., Lu, W., Zhu, W., Xia, T., & Zhou, J. (2024). Severe dawn phenomenon predicts long‐term risk of all‐cause mortality in patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.3813
Vancouver
Cai J, Peng P, Lu J, Shen Y, Wang C, Mo Y, et al. Severe dawn phenomenon predicts long‐term risk of all‐cause mortality in patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews. 2024. doi:10.1002/dmrr.3813
BibTeX
@article{Cai2024,
author = {Cai, Jinghao and Peng, Peng and Lu, Jingyi and Shen, Yun and Wang, Chunfang and Mo, Yifei and Lu, Wei and Zhu, Wei and Xia, Tian and Zhou, Jian},
title = {Severe dawn phenomenon predicts long‐term risk of all‐cause mortality in patients with type 2 diabetes},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2024},
doi = {10.1002/dmrr.3813}
}
EUVIMED